SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026)
SELLAS Life Sciences (SLS) reported Cash from Operations of 8800000.0 for Q1 2026, up 2.98% year-over-year from 8545610.28 in Q1 2025, and down 79.59% quarter-over-quarter from 4900000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Cash from Operations data on file, last reported at 8800000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 8800000.0, up 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was 28130000.0 (up 16.56% YoY), and the FY2025 annual result was 28400000.0, up 19.78% from the prior year.
- Cash from Operations slipped to 8800000.0 in Q1 2026 per SLS's latest filing, from 4900000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4825000.0 in Q4 2023 and troughed at 12127000.0 in Q1 2023.
- A 5-year average of 7518882.35 and a median of 7153000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations plunged 69.61% in 2023, then surged 31.5% in 2025.
- A 5-year view of Cash from Operations shows it stood at 5152000.0 in 2022, then advanced by 6.35% to 4825000.0 in 2023, then plunged by 48.25% to 7153000.0 in 2024, then jumped by 31.5% to 4900000.0 in 2025, then plunged by 79.59% to 8800000.0 in 2026.
- Business Quant data shows SLS's Cash from Operations at 8800000.0 in Q1 2026, 4900000.0 in Q4 2025, and 7100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.80 Mn |
| Mar 31, 2026 | -8.80 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Dec 31, 2023 | -4.83 Mn |